As artificial intelligence (AI) has exploded in popularity in recent years, investors have unsurprisingly scrambled to build exposure to companies they see as likely to benefit from this technological trend. Certainly, one straightforward way to try to achieve this goal is through AI-focused exchange-traded funds (ETFs). Funds like the Global X Artificial Intelligence & Technology ETF NASDAQ: AIQ and the Invesco AI and Next Gen Software ETF NYSEARCA: IGPT give investors a ready-made portfolio of AI-related ...

WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Founder and CEO of Tevogen, Dr. Ryan Saadi, donated 10,000 of his personal shares of common stock to the Opportunity Project, a Millburn, N.J.–based nonprofit dedicated to empowering individuals with brain injuries through its innovative Clubhouse model. Founded in 1993, Opportunity Project has served more than 600 individuals and their families, providing programs that fos ...

Asia Value & Moat Stocks is a research service for value investors seeking Asia-listed stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e., buying assets at a discount, e.g., net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e., buying earnings power at a discount in great companies like "Magic Formula" stocks, high-quality businesses, hidden champions, and wide moat compounders). Sign up here to get s ...

Zeta Global (NYSE: ZETA ) remains a high-conviction idea, even after a 25% surge since my last coverage . Its second-quarter report is a demonstration of the brilliance of disciplined execution, with continued traction across revenue, margins, and free cash flow. What makesHi, I'm Yiannis. Spotting winners before they break out is what I do best.Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certified Accountant, Fellow Member of ACCA Gl ...

Core Viewpoint - Marvel Biosciences Corp. has received a patent for its lead asset MB-204, which is aimed at treating autism spectrum disorder and related conditions, highlighting the company's commitment to addressing significant unmet medical needs in this area [1][3]. Company Overview - Marvel Biosciences Corp. is a Calgary-based biotechnology company focused on developing new treatments for neurological diseases and neurodevelopmental disorders, with MB-204 being a fluorinated derivative of the approved Parkinson's drug Istradefylline [4]. - The company is exploring MB-204's potential in treating conditions such as autism, depression, Alzheimer's disease, and rare disorders like Rett syndrome and Fragile X syndrome [5]. Product Development - MB-204 has shown strong preclinical efficacy across multiple models of autism, Rett syndrome, and depression, and is prepared to enter Phase 1 clinical trials [2]. - The patent granted by the China National Intellectual Property Administration (CNIPA) strengthens Marvel's global intellectual property position, particularly in a key market [1][3]. Market Context - With approximately one in 36 children diagnosed with autism, there is a pressing need for innovative treatments, which underscores the importance of advancing MB-204 through clinical trials [3].

Neils ChristensenNeils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada. He has worked exclusively within the financial sector since 2007, when he started with the Canadian Economic Press. Neils can be contacted at: 1 866 925 4826 ext. 1526 nchristensen at kitco.com @Neils_cShareDisclaimer: The views expressed ...

Core Viewpoint - Hydreight Technologies Inc. has announced a private placement offering of up to C$10,000,000 in unsecured convertible debentures to support its digital healthcare solutions business [1][6] Group 1: Offering Details - The company has granted Canaccord Genuity Corp. an option to increase the offering size by up to C$1,500,000 [2] - The debentures will mature 36 months from issuance and are convertible into common shares at a price of C$4.06 per share [3] - The offering is expected to close around September 4, 2025, pending regulatory approvals [6] Group 2: Financial Terms - The debentures will bear a fixed interest rate of 9.0% per annum, payable semi-annually [5] - The company will pay a cash commission of 6.0% to the lead agent and issue compensation warrants equal to 6.0% of the number of shares issuable upon conversion [7] Group 3: Company Overview - Hydreight Technologies Inc. is building a large mobile clinic network in the U.S., with over 2,500 nurses and 100 doctors across 50 states [10] - The company's platform includes integrated tools for healthcare professionals to provide services directly to patients [10]

Group 1 - The author has a background in private credit and commercial real estate (CRE) mezzanine financing, indicating expertise in financial analysis and investment strategies [1] - The author has collaborated with prominent CRE developers, suggesting a strong network and understanding of the real estate market dynamics [1] - The author is fluent in Mandarin, which may provide an advantage in understanding Asian markets and investment opportunities [1] Group 2 - The article does not provide any specific investment recommendations or financial advice, emphasizing the author's personal opinions and research [2][3][4] - There is no disclosure of any current stock or derivative positions in the companies mentioned, indicating an unbiased perspective [2] - The content is intended for general informational purposes and may not be suitable for all investors, highlighting the importance of individual financial situations [3][4]

Core Viewpoint - REGENXBIO Inc. announced an extension of the FDA review timeline for its Biologics License Application (BLA) for RGX-121, a treatment for Mucopolysaccharidosis II (MPS II), from November 9, 2025, to February 8, 2026 [1] Group 1: FDA Review and Clinical Data - The extension follows the submission of long-term clinical data for all patients in the pivotal study of RGX-121, which included 13 patients, in response to an FDA information request [2] - Positive 12-month clinical data are consistent with previously submitted biomarker and neurodevelopmental data and will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM) in September 2025 [2] - The FDA completed a pre-license inspection and bioresearch monitoring inspection for the RGX-121 BLA with no observations and no safety-related concerns raised during the review [3] Group 2: Company Statements and Designations - The President and CEO of REGENXBIO emphasized the urgent need for a therapeutic option for boys with Hunter syndrome and expressed confidence that commercial launch plans remain on track [4] - RGX-121 has received multiple designations from the FDA, including Orphan Drug Product, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) [4] Group 3: Product and Disease Overview - RGX-121 is a potential one-time AAV therapeutic designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system, potentially providing a permanent source of the I2S protein [5] - MPS II, or Hunter Syndrome, is a rare disease caused by a deficiency in the lysosomal enzyme I2S, leading to significant medical needs, particularly for neurological manifestations [6] Group 4: Future Plans and Market Potential - If approved, RGX-121 would be the first and only commercially available therapy designed to address the underlying genetic cause of Hunter syndrome [8] - REGENXBIO plans to present updated pivotal data during the ICIEM meeting in September 2025 [8]

Core Viewpoint - Obsidian Energy has announced a partial redemption of $30 million of its outstanding Senior Unsecured Notes, reflecting a strong balance sheet and liquidity position, which will help reduce future interest expenses [1][2]. Group 1: Redemption Details - The redemption date is set for August 29, 2025, with a redemption price of $1,029.88 per $1,000 principal amount of the redeemed Notes, equating to 102.988 percent of the principal amount, plus accrued interest [2]. - After the redemption, Obsidian Energy will have $80.8 million of Notes outstanding, and the maximum semi-annual free cash flow offer required under the trust indenture will be $17.0 million [2]. Group 2: Company Overview - Obsidian Energy is an intermediate-sized oil and gas producer with a diverse portfolio of high-quality assets, primarily located in Alberta's Peace River, Willesden Green, and Viking areas [5]. - The company focuses on exploring, developing, and holding interests in oil and natural gas properties and related production infrastructure within the Western Canada Sedimentary Basin [5][6].